Insulin analogues for type 1 diabetes in children and adolescents

Drugs of Today

Volumn 48, Issue 12, 2012, Pages 795-809

  Galli Tsinopoulou, Assimina ^a   Stergidou, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Adolescents; Children; Insulin analogues; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO;

ADVERSE OUTCOME; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOOD INTAKE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; KETOACIDOSIS; LIPOLYSIS; PRACTICE GUIDELINE; REVIEW; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; CHILD; DIABETES MELLITUS, TYPE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ASPART; INSULIN LISPRO; INSULIN, LONG-ACTING;

EID: 84871532196     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.12.1872944     Document Type: Review

References (116)

1. Gale, E.A. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002, 51(12): 3353-61. (Pubitemid 35403436)
2. Karvonen, M., Viik-Kajander, M., Moltchanova, E., Libman, I., LaPorte, R., Tuomilehto, J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000, 23(10): 1516-26.
3. Peter, S. Trends in the incidence of type I diabetes mellitus worldwide. West Indian Med J 2007, 56(3): 264-9. (Pubitemid 350200073)
4. Patterson, C.C., Gyurus, E., Rosenbauer, J. et al. Trends in childhood type 1 diabetes incidence in Europe during 1989- 2008: evidence of non-uniformity over time in rates of increase. Diabetologia 2012, 55(8): 2142-7.
5. Banting, F.G., Best, C.H., Collip, J.B., Campbell, W.R., Fletcher, A.A. Pancreatic extracts in the treatment of diabetes mellitus. Can Med Assoc J 1922, 12(3): 141-6.
6. Gale, E.A. Type 1 diabetes in the young: the harvest of sorrow goes on. Diabetologia 2005, 48(8): 1435-8. (Pubitemid 41175491)
7. Patterson, C.C., Dahlquist, G., Harjutsalo, V. et al. Early mortality in EURODIAB population-based cohorts of type 1 diabetes diagnosed in childhood since 1989. Diabetologia 2007, 50(12): 2439-42. (Pubitemid 350060644)
8. O'Grady, M.J., Delaney, J., Jones, T.W., Davis, E.A. Standardised mortality is increased three-fold in a popula-tion- based sample of children and adolescents with type 1 diabetes. Pediatr Diabetes 2012, 9999(9999):10.1111/ j.1399,5448.2012.00885.x.
9. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329(14): 977-86.
10. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994, 125(2): 177- 88.
11. White, N.H., Cleary, P.A., Dahms, W., Goldstein, D., Malone, J., Tamborlane, W.V,; Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Beneficial effects of intensive therapy of diabetes during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr 2001, 139(6): 804-12. (Pubitemid 34014459)
12. Shield, J.P.H. Relevance of the diabetes control and complications trial to paediatric practice. Current Paediatrics 1997, 7(2): 85-7. (Pubitemid 127703563)
13. Bangstad, H., Danne, T., Deeb, L., Jarosz-Chobot, P., Urakami, T., Hanas, R. Insulin treatment in children and adolescents with diabetes. Pediatric Diabetes 2009, 10: 82-99.
14. Silverstein, J., Klingensmith, G., Copeland, K. et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005, 28(1): 186-212. (Pubitemid 40095803)
15. Steck, A.K., Klingensmith, G.J., Fiallo-Scharer, R. Recent advances in insulin treatment of children. Pediatric Diabetes 2007, 8: 49-56. (Pubitemid 47323767)
16. Phillip, M., Battelino, T., Rodriguez, H. et al. Use of insulin pump therapy in the pediatric age-group: consensus statement from the European Society for Paediatric Endocrinology, the Lawson Wilkins Pediatric Endocrine Society, and the International Society for Pediatric and Adolescent Diabetes, endorsed by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2007, 30(6): 1653-62. (Pubitemid 46871195)
17. Pankowska, E., Blazik, M., Dziechciarz, P., Szypowska, A., Szajewska, H. Continuous subcutaneous insulin infusion vs. multiple daily injections in children with type 1 diabetes: a systematic review and meta-analysis of randomized control trials. Pediatr Diabetes 2009, 10(1): 52-8.
18. Misso, M.L., Egberts, K.J., Page, M., O'Connor, D., Shaw, J. Cochrane review: Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Evidence-Based Child Health: A Cochrane Review Journal 2010, 5(4): 1726-867.
19. Galli-Tsinopoulou, A. Insulin therapy in children and adolescents with diabetes. Diabetes Res Clin Pract 2011, 93(Suppl. 1): S114-7.
20. Williams, R., Dunger, D. Insulin treatment in children and adolescents. Acta Pædiatrica 2004, 93(4): 440-6. (Pubitemid 38469685)
21. Amiel, S.A., Caprio, S., Sherwin, R.S., Plewe, G., Haymond, M.W., Tamborlane, W.V. Insulin resistance of puberty: a defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991, 72(2): 277-82. (Pubitemid 21921688)
22. Swan, K.L., Weinzimer, S.A., Dziura, J.D. et al. Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes. Diabetes Care 2008, 31(1): 44-6.
23. Kordonouri, O., Hartmann, R., Danne, T. Treatment of type 1 diabetes in children and adolescents using modern insulin pumps. Diabetes Res Clin Pract 2011, 93(Suppl. 1): S118-24.
24. Bachran, R., Beyer, P., Klinkert, C., Heidtmann, B., Rosenbauer, J., Holl, R.W.; for the German/Austrian DPV Initiative,the German Pediatric CSII Working Group and the BMBF Competence Network Diabetes. Basal rates and circadian profiles in continuous subcutaneous insulin infusion (CSII) differ for preschool children, prepubertal children, adolescents and young adults. Pediatric Diabetes 2012, 13(1): 1-5.
25. Hirsch, I.B. Insulin analogues. N Engl J Med 2005, 352(2): 174-83. (Pubitemid 40096614)
26. Thompson, R., Christie, D., Hindmarsh, P.C. The role for insulin analogues in diabetes care. Current Paediatrics 2006, 16(2): 117-22. (Pubitemid 43289062)
27. Kapellen, T.M., Wolf, J., Rosenbauer, J., Stachow, R., Ziegler, R., Szczepanski, R., Holl, R.W.; DPV-Science-Initiative. Changes in the use of analogue insulins in 37 206 children and adolescents with type 1 diabetes in 275 German and Austrian centers during the last twelve years. Exp Clin Endocrinol Diabetes 2009, 117(7): 329-35.
28. Rovet, J.F., Ehrlich, R.M. The effect of hypoglycemic seizures on cognitive function in children with diabetes: a 7-year prospective study. J Pediatr 1999, 134(4): 503-6. (Pubitemid 30180635)
29. Shalitin, S., Phillip, M. Hypoglycemia in type 1 diabetes: a still unresolved problem in the era of insulin analogs and pump therapy. Diabetes Care 2008, 31(Suppl. 2): S121-4.
30. Cobry, E., McFann, K., Messer, L., Gage, V., VanderWel, B., Horton, L., Chase, H.P. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther 2010, 12(3): 173-7.
31. Siebenhofer, A., Plank, J., Berghold, A., Narath, M., Gfrerer, R., Pieber, T.R. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2004, (2): CD003287.
32. Plank, J., Siebenhofer, A., Berghold, A., Jeitler, K., Horvath, K., Mrak, P., Pieber, T.R. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005, 165(12): 1337-44. (Pubitemid 40973416)
33. Howey, D.C., Bowsher, R.R., Brunelle, R.L., Woodworth, J.R. Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994, 43(3): 396-402. (Pubitemid 24064246)
34. Deeb, L.C., Holcombe, J.H., Brunelle, R. et al. Insulin lispro lowers postprandial glucose in prepubertal children with diabetes. Pediatrics 2001, 108(5): 1175-9. (Pubitemid 33021195)
35. Ford-Adams, M.E., Murphy, N.P., Moore, E.J. et al. Insulin lispro: a potential role in preventing nocturnal hypoglycaemia in young children with diabetes mellitus. Diabet Med 2003, 20(8): 656-60. (Pubitemid 36966561)
36. Holcombe, J.H., Zalani, S., Arora, V.K., Mast, C.J.; Lispro in Adolescents Study Group. Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents. Clin Ther 2002, 24(4): 629-38. (Pubitemid 34492884)
37. Tupola, S., Komulainen, J., Jaaskelainen, J., Sipila, I. Postprandial insulin lispro vs. human regular insulin in prepubertal children with type 1 diabetes mellitus. Diabet Med 2001, 18(8): 654-8. (Pubitemid 32823063)
38. Murphy, N.P., Keane, S.M., Ong, K.K., Ford-Adams, M., Edge, J.A., Acerini, C.L., Dunger, D.B. Randomized crossover trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003, 26(3): 799- 804.
39. Garcia, L., Lamas, C., Tuset, M.J., Alonso, M., Barrio, R. Treatment with the insulin analogue lispro in children and adolescents with type 1 diabetes mellitus: evaluation over a 3- year period. Diabetes Nutr Metab 2002, 15(1): 7-13. (Pubitemid 34228938)
40. Murphy, N.P., Ford-Adams, M.E., Ong, K.K. et al. Prolonged cardiac repolarisation during spontaneous nocturnal hypoglycaemia in children and adolescents with type 1 diabetes. Diabetologia 2004, 47(11): 1940-7. (Pubitemid 40110202)
41. Brunelle, B.L., Llewelyn, J., Anderson, J.H. Jr., Gale, E.A., Koivisto, V.A. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 1998, 21(10): 1726-31. (Pubitemid 28449815)
42. Mohn, A., Matyka, K.A., Harris, D.A., Ross, K.M., Edge, J.A., Dunger, D.B. Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight. Diabetes Care 1999, 22(1): 27-32. (Pubitemid 29028294)
43. Raskin, P., Holcombe, J.H., Tamborlane, W.V., Malone, J.I., Strowig, S., Ahern, J.A., Lavent, F. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump. J Diabetes Complications 2001, 15(6): 295-300. (Pubitemid 33065671)
44. Kaiserman, K., Rodriguez, H., Stephenson, A., Wolka, L., Fahrbach, J.L. Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus. Endocr Pract 2012, 18(3): 418-24.
45. Della Manna, T., Steinmetz, L., Campos, P.R. et al. Subcutaneous use of a fast-acting insulin analog: an alternative treatment for pediatric patients with diabetic ketoacidosis. Diabetes Care 2005, 28(8): 1856-61. (Pubitemid 41060954)
46. Wolfsdorf, J., Craig, M.E., Daneman, D. et al. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes 2009, 10(Suppl. 12): 118-33.
47. Kamoi, K., Miyakoshi, M., Maruyama, R. A quality-of-life assessment of intensive insulin therapy using insulin lispro switched from short-acting insulin and measured by an ITRQOL questionnaire: a prospective comparison of multiple daily insulin injections and continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 2004, 64(1): 19-25. (Pubitemid 38249454)
48. Grey, M., Boland, E.A., Tamborlane, W.V. Use of lispro insulin and quality of life in adolescents on intensive therapy. Diabetes Educ 1999, 25(6): 934-41.
49. Miles, H.L., Acerini, C.L. Insulin analog preparations and their use in children and adolescents with type 1 diabetes mellitus. Paediatr Drugs 2008, 10(3): 163-76. (Pubitemid 351629672)
50. Cengiz, E., Tamborlane, W.V., Martin-Fredericksen, M., Dziura, J., Weinzimer, S.A. Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care 2010, 33(5): 1009-12.
51. Home, P.D., Barriocanal, L., Lindholm, A. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. Eur J Clin Pharmacol 1999, 55(3): 199-203. (Pubitemid 29244647)
52. Mortensen, H.B., Lindholm, A., Olsen, B.S., Hylleberg, B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr 2000, 159(7): 483-8. (Pubitemid 30418989)
53. Heller, S., McCance, D.R., Moghissi, E., Nazeri, A., Kordonouri, O. Diversity in diabetes: the role of insulin aspart. Diabetes Metab Res 2012, 28(1): 50-61.
54. Danne, T. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus. Clin Ther 2007, 29(Suppl. D): S145-52.
55. Luijf, Y.M., van Bon, A.C., Hoekstra, J.B., Devries, J.H. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care 2010, 33(10): 2152-5.
56. Danne, T., Rastam, J., Odendahl, R. et al. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes. Pediatr Diabetes 2007, 8(5): 278-85. (Pubitemid 47422901)
57. Danne, T., Aman, J., Schober, E., Deiss, D., Jacobsen, J.L., Friberg, H.H., Jensen, L.H.; ANA 1200 Study Group. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003, 26(8): 2359-64. (Pubitemid 36993326)
58. Weinzimer, S.A., Ternand, C., Howard, C., Chang, C.T., Becker, D.J., Laffel, L.M.; Insulin Aspart Pediatric Pump Study Group. A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes. Diabetes Care 2008, 31(2): 210-5. (Pubitemid 351213321)
59. Doyle, E.A., Weinzimer, S.A., Steffen, A.T., Ahern, J.A., Vincent, M., Tamborlane, W.V. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004, 27(7): 1554-8. (Pubitemid 38857425)
60. Nguyen, T.M., Renukuntla, V.S., Heptulla, R.A. Mixing insulin aspart with detemir does not affect glucose excursion in children with type 1 diabetes. Diabetes Care 2010, 33(8): 1750-2.
61. Cengiz, E., Swan, K.L., Tamborlane, W.V., Sherr, J.L., Martin, M., Weinzimer, S.A. The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin. Diabetes Care 2012, 35(4): 690-2.
62. Babiker, A., Datta, V. Lipoatrophy with insulin analogues in type I diabetes. Arch Dis Child 2011, 96(1): 101-2.
63. Swelheim, H.T., Westerlaken, C., van Pinxteren-Nagler, E., Bocca, G. Lipoatrophy in a girl with type 1 diabetes: beneficial effects of treatment with a glucocorticoid added to an insulin analog. Diabetes Care 2012, 35(3): e22.
64. Danne, T., Becker, R.H., Heise, T., Bittner, C., Frick, A.D., Rave, K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005, 28(9): 2100-5. (Pubitemid 41242451)
65. Becker, R.H., Frick, A.D., Burger, F., Scholtz, H., Potgieter, J.H. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005, 113(5): 292-7. (Pubitemid 40868186)
66. Becker, R.H., Frick, A.D. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008, 47(1): 7-20. (Pubitemid 350260885)
67. Heise, T., Nosek, L., Spitzer, H., Heinemann, L., Niemoller, E., Frick, A.D., Becker, R.H. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 2007, 9(5): 746-53. (Pubitemid 47261856)
68. Arnolds, S., Rave, K., Hovelmann, U., Fischer, A., Sert- Langeron, C., Heise, T. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes 2010, 118(9): 662-4.
69. Philotheou, A., Arslanian, S., Blatniczky, L., Peterkova, V., Souhami, E., Danne, T. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes. Diabetes Technol Ther 2011, 13(3): 327-34.
70. Lih, A., Hibbert, E., Wong, T., Girgis, C.M., Garg, N., Carter, J.N. The role of insulin glulisine to improve glycemic control in children with diabetes mellitus. Diabetes Metab Syndr Obes 2010, 3: 403-12.
71. Umpierrez, G.E., Jones, S., Smiley, D. et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. Diabetes Care 2009, 32(7): 1164-9.
72. Bode, B.W. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapidacting insulin analogues-aspart, lispro, and glulisine. Endocr Pract 2011, 17(2): 271-80.
73. Heller, S., Buse, J., Fisher, M. et al. Insulin degludec, an ultralongacting basal insulin, versus insulin glargine in basalbolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012, 379(9825): 1489-97.
74. Devries, J.H., Nattrass, M., Pieber, T.R. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007, 23(6): 441-54. (Pubitemid 47526934)
75. Edge, J.A., Ford-Adams, M.E., Dunger, D.B. Causes of death in children with insulin dependent diabetes 1990-96. Arch Dis Child 1999, 81(4): 318-23. (Pubitemid 29467769)
76. Tattersall, R.B., Gill, G.V. Unexplained deaths of type 1 diabetic patients. Diabet Med 1991, 8(1): 49-58.
77. Little, S., Shaw, J., Home, P. Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 2011, 13(Suppl. 1): S53-64.
78. Pieber, T.R., Eugene-Jolchine, I., Derobert, E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000, 23(2): 157-62. (Pubitemid 30071017)
79. Owens, D.R., Coates, P.A., Luzio, S.D., Tinbergen, J.P., Kurzhals, R. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000, 23(6): 813-9. (Pubitemid 30414199)
80. Mohn, A., Strang, S., Wernicke-Panten, K., Lang, A.M., Edge, J.A., Dunger, D.B. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 2000, 23(4): 557-9. (Pubitemid 30185805)
81. European Medicines Agency. 2012; Available at: http://www.ema.europa.eu/ ema/index.jsp?curl=pages/medicines/human/medicines/000284/smops/Positive/ human-smop-000370.jsp&mid=WC0b01ac058001d127.
82. Alemzadeh, R., Berhe, T., Wyatt, D.T. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 2005, 115(5): 1320-4. (Pubitemid 43843238)
83. Dixon, B., Chase, H.P., Burdick, J. et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes 2005, 6(3): 150-4. (Pubitemid 41223240)
84. Colino, E., Lopez-Capape, M., Golmayo, L., Alvarez, M.A., Alonso, M., Barrio, R. Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract 2005, 70(1): 1-7. (Pubitemid 41207640)
85. Deiss, D., Kordonouri, O., Hartmann, R., Hopfenmuller, W., Lupke, K., Danne, T. Treatment with insulin glargine reduces asymptomatic hypoglycemia detected by continuous subcutaneous glucose monitoring in children and adolescents with type 1 diabetes. Pediatr Diabetes 2007, 8(3): 157-62. (Pubitemid 46864297)
86. Chase, H.P., Dixon, B., Pearson, J. et al. Reduced hypoglycemic episodes and improved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pediatr 2003, 143(6): 737-40. (Pubitemid 37510641)
87. White, N.H., Chase, H.P., Arslanian, S., Tamborlane, W.V.; 4030 Study Group. Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes. Diabetes Care 2009, 32(3): 387-93.
88. Schober, E., Schoenle, E., Van Dyk, J., Wernicke-Panten, K.; Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002, 15(4): 369-76. (Pubitemid 34704801)
89. Chase, H.P., Arslanian, S., White, N.H., Tamborlane, W.V. Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus. J Pediatr 2008, 153(4): 547-53.
90. Starkman, H., Frydman, E., Bustami, R. Glargine basalbolus insulin regimen versus insulin pump therapy: comparison of glycemic control. J Pediatr Endocrinol Metab 2011, 24(5-6): 369-71.
91. Alemzadeh, R., Ellis, J.N., Holzum, M.K., Parton, E.A., Wyatt, D.T. Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. Pediatrics 2004, 114(1): e91-5.
92. Karges, B., Kapellen, T., Neu, A. et al. Long-acting insulin analogs and the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes: a prospective study of 10,682 patients from 271 institutions. Diabetes Care 2010, 33(5): 1031-3.
93. Kurtzhals, P., Schaffer, L., Sorensen, A., Kristensen, C., Jonassen, I., Schmid, C., Trub, T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000, 49(6): 999-1005. (Pubitemid 30349423)
94. Andersson, C., Vaag, A., Selmer, C. et al. Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people. BMJ Open 2012, 2(3), pii: e000433.
95. Buchs, A.E., Silverman, B.G. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. Metabolism 2011, 60(10): 1379-85.
96. Hemkens, L.G., Grouven, U., Bender, R., Gunster, C., Gutschmidt, S., Selke, G.W., Sawicki, P.T. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009, 52(9): 1732-44.
97. Ruiter, R., Visser, L.E., van Herk-Sukel, M.P. et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012, 55(1): 51-62.
98. Jonasson, J.M., Ljung, R., Talback, M., Haglund, B., Gudbjornsdottir, S., Steineck, G. Insulin glargine use and shortterm incidence of malignancies - a population-based followup study in Sweden. Diabetologia 2009, 52(9): 1745-54.
99. Weinstein, D., Simon, M., Yehezkel, E., Laron, Z., Werner, H. Insulin analogues display IGF-I-like mitogenic and antiapoptotic activities in cultured cancer cells. Diabetes Metab Res Rev 2009, 25(1): 41-9.
100. .Ciaraldi, T.P., Carter, L., Seipke, G., Mudaliar, S., Henry, R.R. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 2001, 86(12): 5838-47. (Pubitemid 33152632)
101. Ciaraldi, T.P., Sasaoka, T. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system: potential implications for metabolic and mitogenic activities. Horm Metab Res 2011, 43(1): 1-10.
102. .Edwards, K.L., Riche, D.M., Stroup, J.S., Goldman-Levine, J.D., Padiyara, R.S., Cross, L.B., Kane, M.P. Insulin glargine and cancer risk: an opinion statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2010, 30(9): 955-65.
103. Sciacca, L., Le Moli, R., Vigneri, R. Insulin analogs and cancer. Front Endocrinol (Lausanne) 2012, 3: 21.
104. .Grouven, U., Hemkens, L.G., Bender, R., Sawicki, P.T. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Reply to Nagel JM, Mansmann U, Wegscheider K et al. [letter] and Simon D [letter. Diabetologia 2010, 53(1): 209-11.
105. .Kurtzhals, P., Havelund, S., Jonassen, I., Kiehr, B., Larsen, U.D., Ribel, U., Markussen, J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J 1995, 312(Pt. 3): 725-31. (Pubitemid 26005980)
106. .Plank, J., Bodenlenz, M., Sinner, F. et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005, 28(5): 1107-12. (Pubitemid 40616620)
107. Valensi, P., Cosson, E. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects? Diabetes Metab 2005, 31(4, Pt. 2): 4S34-9.
108. .Porcellati, F., Rossetti, P., Busciantella, N.R. et al. Comparison of pharmacokinetics and dynamics of the longacting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care 2007, 30(10): 2447-52. (Pubitemid 47547770)
109. .Danne, T., Lupke, K., Walte, K., Von Schuetz, W., Gall, M.A. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003, 26(11): 3087-92. (Pubitemid 37339503)
110. Szypowska, A., Golicki, D., Groele, L., Pankowska, E. Longacting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and meta-analysis. Pol Arch Med Wewn 2011, 121(7-8): 237-46.
111. Thalange, N., Bereket, A., Larsen, J., Hiort, L.C., Peterkova, V. Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1 diabetes mellitus. Pediatric Diabetes 2011, 12(7): 632-41.
112. Robertson, K.J., Schoenle, E., Gucev, Z., Mordhorst, L., Gall, M.A., Ludvigsson, J. Insulin detemir compared with NPH insulin in children and adolescents with type 1 diabetes. Diabet Med 2007, 24(1): 27-34. (Pubitemid 46103068)
113. Pieber, T.R., Treichel, H.C., Hompesch, B., Philotheou, A., Mordhorst, L., Gall, M.A., Robertson, L.I. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med 2007, 24(6): 635-42. (Pubitemid 46808860)
114. Heller, S., Koenen, C., Bode, B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther 2009, 31(10): 2086-97.
115. Danne, T., Datz, N., Endahl, L. et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes 2008, 9(6): 554-60.
116. Dejgaard, A., Lynggaard, H., Rastam, J., Krogsgaard Thomsen, M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a metaanalysis. Diabetologia 2009, 52(12): 2507-12.